In this multistate population-based cohort study across 8 cancer registries, residence in counties with a higher prevalence of PSA screening was associated with lower odds of advanced disease stage, lower all-cause mortality, and lower prostate cancer–specific mortality. The gene discussed is KLK3; the disease is prostate carcinoma.